{"title":"Why Biosimilars Matter: An Innovative Solution to Improve Patient Access","authors":"Lynda M. McEvoy","doi":"10.33590/emjhematol/10311696","DOIUrl":null,"url":null,"abstract":"The meeting was introduced by Prof Robin Foà who spoke about the difficulties for patients accessing therapies in the context of rising healthcare costs and reduced budgets. Dr Mark McCamish then explained the biosimilar development process and the analytical techniques involved. Prof Felix Keil discussed the role of biosimilar medicines in haematology using the example of GP2013/rituximab (RTX), and Ms Karen Van Rassel of the Lymphoma Coalition presented the role a patient organisation can play when working with the physician to support a patient’s questions and concerns regarding lymphoma.","PeriodicalId":326555,"journal":{"name":"EMJ Hematology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMJ Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33590/emjhematol/10311696","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The meeting was introduced by Prof Robin Foà who spoke about the difficulties for patients accessing therapies in the context of rising healthcare costs and reduced budgets. Dr Mark McCamish then explained the biosimilar development process and the analytical techniques involved. Prof Felix Keil discussed the role of biosimilar medicines in haematology using the example of GP2013/rituximab (RTX), and Ms Karen Van Rassel of the Lymphoma Coalition presented the role a patient organisation can play when working with the physician to support a patient’s questions and concerns regarding lymphoma.
Robin focom教授介绍了这次会议，他谈到了在医疗成本上升和预算减少的背景下，患者获得治疗的困难。马克·麦卡米什博士随后解释了生物仿制药的开发过程和所涉及的分析技术。Felix Keil教授以GP2013/rituximab (RTX)为例讨论了生物仿制药在血液学中的作用，淋巴瘤联盟的Karen Van Rassel女士介绍了患者组织在与医生合作支持患者关于淋巴瘤的问题和担忧时可以发挥的作用。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
